1. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv 2020.04.23.20076042. https://doi.org/10.1101/2020.04.23.20076042

2. Li B, Yang J, Zhao F, Zhi L, Wang X et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531–538. https://doi.org/10.1007/s00392-020-01626-9

3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;Feb 24. https://doi.org/10.1001/jama.2020.2648.

4. Clemente GS, Rickmeier J, Antunes IF, Zarganes-Tzitzikas T, Dömling A, Ritter T, et al. [18F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statinrelated mechanisms of action. EJNMMI Res. 2020;10(1):34. https://doi.org/10.1186/s13550-020-00622-4.

5. Ambrose JA, Martinez EE. A new paradigm for plaque stabilization. Circulation. 2002;105(16):2000-4. https://doi.org/10.1161/01.cir.0000012528.89469.8e.

6. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001;103(2):276-83. https://doi.org/10.1161/01.cir.103.2.276.

7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. https://doi.org/10.1016/S0140-6736(20)30937-5.

8. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559-1561. https://doi.org/10.1111/jth.14849.

9. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020; Mar 27. https://doi.org/10.1001/jamacardio.2020.1286. Epub ahead of print.

10. Hu T, Chen B, Zhou S, Mao J. Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. Int J Clin Exp Pathol. 2018;11(8):3925-3933. PMID: 31949780.

11. Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T, et al. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. J Clin Med. 2019;8(12):2051. https://doi.org/10.3390/jcm8122051.

12. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and metaanalysis. Lancet Haematol. 2017;4(2):e83-e93. https://doi.org/10.1016/S2352-3026(16)30184-3.

13. Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J. 2017;38(20):1608-1612. https://doi.org/10.1093/eurheartj/ehx107

14. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20-8. https://doi.org/10.1056/NEJMoa042378.

15. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307-16. https://doi.org/10.1001/jama.292.11.1307.

16. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64-70. https://doi.org/10.1001/jama.286.1.64.

17. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959-65. https://doi.org/10.1056/NEJM200106283442601.

18. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of lowdensity lipoprotein cholesterol reduction. Circulation. 2002;106(12):1447-52. https://doi.org/10.1161/01.cir.0000029743.68247.31.

19. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 2006;54(2):579-86. https://doi.org/10.1002/art.21564

20. Geng J, Xu H, Yu X, Xu G, Cao H, Lin G, et al. Rosuvastatin protects against oxidized low density lipoprotein induced endothelial cell injury of atherosclerosis in vitro. Mol Med Rep. 2019;19(1):432-440. https://doi.org/10.3892/mmr.2018.9666.

21. Yinjuan T, Jianjun W, Yinglu G, Weijun C, Weijun T, Mingying L. [Effect of atorvastatin on LOX-1 and eNOS expression in collateral vessels of hypercholesterolemic rats]. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(11):1265-1272. https://doi.org/10.12122/j.issn.1673-4254.2019.11.01. (in Chineese)

22. Hostenbach S, D'Haeseleer M, Kooijman R, De Keyser J. Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis. Front Pharmacol. 2020;10:1491. https://doi.org/10.3389/fphar.2019.01491

23. Aslam M, Troidl C, Tanislav C, Rohrbach S, Gündüz D, Hamm CW. Inhibition of Protein Prenylation of GTPases Alters Endothelial Barrier Function. Int J Mol Sci. 2019;21(1):2. https://doi.org/10.3390/ijms21010002.

24. John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005;149(3):473. https://doi.org/10.1016/j.ahj.2004.06.027

25. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103(18):2248-53. https://doi.org/10.1161/01.cir.103.18.2248.

26. Chang SN, Wu CK, Lai LP, Chiang FT, Hwang JJ, Tsai CT. The effect and molecular mechanism of statins on the expression of human anti-coagulation genes. Cell Mol Life Sci. 2019;76(19):3891-3898. https://doi.org/10.1007/s00018-019-03100-w.

27. Violi F, Carnevale R, Pastori D, Pignatelli P. Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition. Trends Cardiovasc Med. 2014;24(4):142-8. https://doi.org/10.1016/j.tcm.2013.09.006.

28. Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/ Rho-kinase and Akt pathways. Circulation. 2002;105(15):1756- 9. https://doi.org/10.1161/01.cir.0000015465.73933.3b.

29. Schol-Gelok S, van der Hulle T, Biedermann JS, van Gelder T, Klok FA, van der Pol LM, et al. Clinical effects of antiplatelet drugs and statins on D-dimer levels. Eur J Clin Invest. 2018;48(7):e12944. https://doi.org/10.1111/eci.12944.

30. Oesterle A, Liao JK. The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. Curr Vasc Pharmacol. 2019;17(3):222-232. https://doi.org/10.2174/1570161116666180817155058.

31. Laufs U, Gertz K, Huang P, Nickenig G, Böhm M, Dirnagl U, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31(10):2442-9. https://doi.org/10.1161/01.str.31.10.2442.

32. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23(1):58-63. https://doi.org/10.1161/01.atv.0000043456.48735.20.

33. Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol. 2010;159(6):1294-303. https://doi.org/10.1111/j.1476-5381.2009.00612.x.

34. Kagami S, Owada T, Kanari H, Saito Y, Suto A, Ikeda K, et al. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol. 2009;21(6):679-89. https://doi.org/10.1093/intimm/dxp037.

35. Gilbert R, Al-Janabi A, Tomkins-Netzer O, Lightman S. Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis. Porto Biomed J. 2017;2(2):33-39. https://doi.org/10.1016/j.pbj.2017.01.006.

36. Jameel A, Ooi KG, Jeffs NR, Galatowicz G, Lightman SL, Calder VL. Statin Modulation of Human T-Cell Proliferation, IL-1β and IL-17 Production, and IFN-γ T Cell Expression: Synergy with Conventional Immunosuppressive Agents. Int J Inflam. 2013;2013:434586. https://doi.org/10.1155/2013/434586.

37. Krysiak R, Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol. 2011;57(4):505-12. https://doi.org/10.1097/FJC.0b013e318211703b.

38. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7(6):687-92. https://doi.org/10.1038/89058.

39. Yuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio. 2015;6(4):e01120. https://doi.org/10.1128/mBio.01120-15.

40. Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT, et al. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. mBio. 2015;6(3):e00638-15. https://doi.org/10.1128/mBio.00638-15.

41. Yuan X, Deng Y, Guo X, Shang J, Zhu D, Liu H. Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathway. Biochem Biophys Res Commun. 2014;446(1):292-7. https://doi.org/10.1016/j.bbrc.2014.02.091.

42. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res. 2013;99:417–35. https://doi.org/10.1016/j.antiviral.2013.06.018

43. Fedson DS. Clinician-initiated research on treating the host response to pandemic influenza. Hum Vaccin Immunother. 2018;14(3):790-795. https://doi.org/10.1080/21645515.2017.1378292.

44. Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. Biomed Res Int. 2014;2014:872370. https://doi.org/10.1155/2014/872370.

45. Kumaki Y, Morrey JD, Barnard DL. Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virol. 2012;7(8):801-818. https://doi.org/10.2217/fvl.12.71

46. Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Version 2. Proc Natl Acad Sci U S A. 2007;104(30):12479- 81. https://doi.org/10.1073/pnas.0705289104.

47. Belser JA, Szretter KJ, Katz JM, Tumpey TM. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice. Virology. 2013;439(1):42-6. https://doi.org/10.1016/j.virol.2013.01.017.

48. Radigan KA, Urich D, Misharin AV, Chiarella SE, Soberanes S, Gonzalez A, et al. The effect of rosuvastatin in a murine model of influenza A infection. PLoS One. 2012;7(4):e35788. https://doi.org/10.1371/journal.pone.0035788.

49. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006-12. https://doi.org/10.1378/chest.06-1997.

50. Atamna A, Babitch T, Bracha M, Sorek N, Haim BZ, Elis A, et al. Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza. Eur J Clin Microbiol Infect Dis. 2019;38(12):2341-2348. https://doi.org/10.1007/s10096-019-03684-y.

51. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, et al. Association between use of statins and mortality among patients hospitalized with laboratoryconfirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205(1):13-9. https://doi.org/10.1093/infdis/jir695.

52. Pawelka E, Karolyi M, Daller S, Kaczmarek C, Laferl H, Niculescu I, et al. Influenza virus infection: an approach to identify predictors for in-hospital and 90-day mortality from patients in Vienna during the season 2017/18. Infection. 2020;48(1):51-56. https://doi.org/10.1007/s15010-019-01335-0.

53. Fedson DS. A practical treatment for patients with Ebola virus disease. J Infect Dis. 2015;211(4):661-2. https://doi.org/10.1093/infdis/jiu474.

54. Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, Thickett DR, et al. Simvastatin decreases lipopolysaccharideinduced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med. 2009;179(12):1107-14. https://doi.org/10.1164/rccm.200810-1584OC.

55. Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock. 2009;31(5):500-6. https://doi.org/10.1097/SHK.0b013e318189017a.

56. Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, et al. Angiotensinconverting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep. 2015;5:8209. https://doi.org/10.1038/srep08209.

57. Fedson DS. Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med. 2016;4(21):421. https://doi.org/10.21037/atm.2016.11.03.

58. Fedson DS, Jacobson JR, Rordam OM, Opal SM. Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers. mBio. 2015;6(3):e00716. https://doi.org/10.1128/mBio.00716-15.

59. Fedson DS, Rordam OM. Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers. Int J Infect Dis 2015;36:80–84. https://doi.org/10.1016/j.ijid.2015.04.019

60. Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a LongLived Enemy. Front Immunol. 2019;10:531. https://doi.org/10.3389/fimmu.2019.00531.

61. Reiner Ž, Hatamipour M, Banach M, Pirro M, Al-Rasadi K, Jamialahmadi T, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(3):490-496. https://doi.org/10.5114/aoms.2020.94655.

62. De Spiegeleer A, Bronselaer A, Teo JT, Byttebier G, De Tré G, Belmans L, et al. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. J Am Med Dir Assoc. 2020;21(7):909–914. e2. https://doi.org/10.1016/j.jamda.2020.06.018.

63. Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. InHospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020:S1550-4131(20)30316-8. https://doi.org/10.1016/j.cmet.2020.06.015.

64. Rodrigues-Diez RR, Tejera-Muñoz A, Marquez-Exposito L, Rayego-Mateos S, Santos Sanchez L, Marchant V, et al. Statins: Could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020:10.1111/bph.15166. https://doi.org/10.1111/bph.15166. Epub ahead of print.

65. Scicali R, Di Pino A, Piro S, Rabuazzo AM, Purrello F. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects? Nutr Metab Cardiovasc Dis. 2020;30(7):1068-1069. https://doi.org/10.1016/j.numecd.2020.05.003.

66. Neufeldt CJ, Cortese M, Acosta EG, Bartenschlager R. Rewiring cellular networks by members of the Flaviviridae family. Nat Rev Microbiol. 2018;16(3):125-142. https://doi.org/10.1038/nrmicro.2017.170.

67. Glende J, Schwegmann-Wessels C, Al-Falah M, Pfefferle S, Qu X, Deng H, et al. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensinconverting enzyme 2. Virology. 2008;381(2):215-21. https://doi.org/10.1016/j.virol.2008.08.026.

68. Soto-Acosta R, Mosso C, Cervantes-Salazar M, Puerta-Guardo H, Medina F, Favari L, et al. The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity. Virology. 2013;442(2):132-47. https://doi.org/10.1016/j.virol.2013.04.003.

69. Шляхто Е.В., Конради А.О., Арутюнов Г.П., Арутюнов А.Г., Баутин А.Е., Бойцов С.А., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. https://doi.org/10.15829/1560-4071-2020-3-3801

70. Шляхто Е.В., Арутюнов Г.П., Беленков Ю.Н., Тарловская Е.И., Конради А.О., Панченко Е.П., и др. Применение статинов, антикоагулянтов, антиагрегантов и антиаритмических препаратов у пациентов с COVID-19. Кардиология. 2020;60(6):4–14. https://doi.org/10.18087/cardio.2020.6.n1180

71. Арутюнов Г.П., Козиолова Н.А., Болдина М.В., Батюшин М.М., Аметов А.С., Арутюнов А.Г., и др. Согласованная позиция экспертов Евразийской ассоциации терапевтов по вопросам тактики ведения пациентов c коморбидной патологией, инфицированных SARS-Cov-2. Терапевтический архив. 2020;92(9). https://doi.org/10.26442/00403660.2020.09.000703